Work Group on Major Depressive Disorder.
Practice Guideline for the Treatment of Patients with Major Depressive Disorder.
American Psychiatric Association, 2010.
National Collaborating Centre for Mental Health.
Depression: The Treatment and Management of Depression in Adults (Update).
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde.
S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression Langfassung [S3 Guideline/National Guideline Unipolar Depressive Disorder] (version 1.3.): 264. Ärztliches Zentrum für Qualität in der Medizin, 2012.
Ioannidis, JP, Evans, SJ, Gotzsche, PC, O'Neill, RT, Altman, DG, Schulz, K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med
2004; 141: 781–8.
Kirsch, I. The Emperor's New Drugs: Exploding the Antidepressant Myth.
Basic Books, 2009.
Moncrieff, J. Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis
2001; 189: 288–95.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med
2008; 358: 252–60.
Greenberg, RP, Bornstein, RF, Zborowski, MJ, Fisher, S, Greenberg, MD. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis
1994; 182: 547–51.
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry
1960; 23: 56–62.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Higgins, JPT, Deeks, JJ. Selecting studies and collecting data. In Cochrane Handbook for Systematic Reviews of Interventions (eds Higgins, JPT, Green, S): 151–85. Wiley, 2008.
Higgins, JPT, Deeks, JJ. Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions (eds Higgins, JPT, Green, S): 187–235. Wiley, 2008.
DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials
1986; 7: 177–88.
Lipsey, MW, Wilson, DB. Practical Meta-Analysis.
Cusin, C, Yang, H, Yeung, A, Fava, M. Rating scales for depression. In Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health (eds Baer, L, Blais, MA): 7–36. Humana Press, 2010.
Gartlehner, G, Hansen, RA, Thieda, P, DeVeaugh-Geiss, AM, Gaynes, BN, Krebs, EE, et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness Review No. 7.
Agency for Healthcare Research and Quality, 2007.
Papakostas, GI, Fava, M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol
2009; 19: 34–40.
Baron, RM, Kenny, DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol
1986; 51: 1173–82.
MacKinnon, DP, Fairchild, AJ, Fritz, MS. Mediation analysis. Annu Rev Psychol
2007; 58: 593–614.
Sobel, ME. Asymptotic confidence intervals for indirect effects in structural equations models. In Sociological Methodology (ed. Leinhart, S): 290–312. Jossey-Bass, 1982.
Sobel, ME. Some new results on indirect effects and their standard errors in covariance structure models. In Sociological Methodology 1986 (ed. Tuma, N): 159–86. American Sociological Association, 1986.
Aroian, LA. The probability function of the product of two normally distributed variables. Ann Math Stat
1944; 18: 265–71.
MacKinnon, DP, Lockwood, CM, Hoffman, JM, West, SG, Sheets, V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods
2002; 7: 83–104.
Barbui, C, Furukawa, TA, Cipriani, A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ
2008; 178: 296–305.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med
2008; 5: e45.
Baethge, C, Asall, OP, Baldessarini, RJ. Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000–2010. Psychother Psychosom
2013; 82: 152–60.
Bello, S, Moustgaard, H, Hrobjartsson, A. The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications. J Clin Epidemiol
2014; 67: 1059–69.
Moher, D, Hopewell, S, Schulz, KF, Montori, V, Gotzsche, PC, Devereaux, PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ
2010; 340: c869.
Rief, W, Nestoriuc, Y, von Lilienfeld-Toal, A, Dogan, I, Schreiber, F, Hofmann, SG, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf
2009; 32: 1041–56.
Shedden Mora, M, Nestoriuc, Y, Rief, W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci
2011; 366: 1879–88.
Rief, W, Avorn, J, Barsky, AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med
2006; 166: 155–60.
Colloca, L, Benedetti, F. How prior experience shapes placebo analgesia. Pain
2006; 124: 126–33.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Dimidjian, S, Amsterdam, JD, Shelton, RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA
2010; 303: 47–53.
Gibbons, RD, Hur, K, Brown, CH, Davis, JM, Mann, JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry
2012; 69: 572–9.